Bupropion may increase risk of psoriasis exacerbation
- PDF / 150,655 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 11 Downloads / 207 Views
1
Bupropion may increase risk of psoriasis exacerbation New Zealand’s Medicines and Medical Devices Safety Authority, Medsafe, reports that bupropion may be associated with an increased risk of psoriasis exacerbation. This potential safety concern was triggered by a case reported to the Centre for Adverse Reactions Monitoring (CARM) describing exacerbation of psoriasis 15 days after initiation of bupropion [Zyban modified-release tablet; GlaxoSmithKline] for smoking cessation. Other case reports have been published of patients with pre-existing and well-controlled psoriasis who experienced psoriasis exacerbation within two weeks after initiating bupropion. In most cases, the exacerbation resolved when bupropion was discontinued. Medsafe is placing this safety concern on the Medicines Monitoring scheme and will continue monitoring this risk until 29 March 2021. It is encouraging patients and healthcare professionals to report psoriasis excarbations or newonset psoriasis in patients receiving bupropion to CARM. Medsafe. Possible risk of psoriasis exacerbation with bupropion. Internet Document : 29 Sep 2020. Available from: URL: https://www.medsafe.govt.nz/safety/Alerts/ PsoriasisWithBupropion.asp
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803507712
Reactions 17 Oct 2020 No. 1826
Data Loading...
